Form 8-K - Current report:
SEC Accession No. 0001753926-24-001759
Filing Date
2024-10-24
Accepted
2024-10-24 08:30:35
Documents
14
Period of Report
2024-10-22
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K g084503_8k.htm   iXBRL 8-K 57170
2 EXHIBIT 99.1 g084503_ex99-1.htm EX-99.1 11165
  Complete submission text file 0001753926-24-001759.txt   249753

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE chro-20241022.xsd EX-101.SCH 3021
4 XBRL LABEL FILE chro-20241022_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE chro-20241022_pre.xml EX-101.PRE 22363
16 EXTRACTED XBRL INSTANCE DOCUMENT g084503_8k_htm.xml XML 3863
Mailing Address 685 US HIGHWAY ONE NORTH BRUNSWICK NJ 08902
Business Address 685 US HIGHWAY ONE NORTH BRUNSWICK NJ 08902 9176446313
Chromocell Therapeutics Corp (Filer) CIK: 0001919246 (see all company filings)

EIN.: 863335449 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41964 | Film No.: 241390821
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)